GSK plc (LSE/NYSE: GSK) today announced that it has completed the primary objective data analysis from the phase II part of the TH HSV REC-003 trial. This trial is a combined phase I/II proof-of-concept study to assess potential clinical efficacy of GSK3943104, an early-stage therapeutic herpes simplex virus (HSV) vaccine candidate, before progressing it for further clinical development..

葛兰素史克股份有限公司（伦敦证交所/纽约证交所：葛兰素史克）今天宣布，它已经完成了第二阶段HSV REC-003试验的主要客观数据分析。

Results show that GSK3943104 did not meet the study’s primary efficacy objective. This vaccine candidate, therefore, will not progress to phase III studies. No safety concern was observed. The TH HSV REC-003 study will continue for routine safety monitoring and to generate follow-up data that could offer valuable insights into recurrent genital herpes.

结果显示，GSK3943104不符合研究的主要疗效目标。因此，这种候选疫苗不会进入III期研究。没有观察到安全问题。TH HSV REC-003研究将继续进行常规安全监测，并产生随访数据，这些数据可能为复发性生殖器疱疹提供有价值的见解。

GSK is working closely with investigators to inform trial participants..

GSK正在与调查人员密切合作，告知试验参与者。。

Given the unmet medical need and burden associated with genital herpes, innovation in this area is still needed. GSK intends to evaluate the totality of all these data and other studies to progress future research and development of its HSV programme.

鉴于生殖器疱疹相关的医疗需求和负担尚未得到满足，这一领域仍需要创新。葛兰素史克打算评估所有这些数据和其他研究的总和，以推进其HSV计划的未来研究和开发。

About GSK

GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

葛兰素史克是一家全球性生物制药公司，旨在将科学、技术和人才团结起来，共同战胜疾病。更多信息请访问gsk.com。